{"disease":{"id":"luminal-b-her2-negative-breast-cancer","name":"luminal b her2 negative breast cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06525675","title":"Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)","phase":"","overall_status":"COMPLETED","enrollment_count":419,"lead_sponsor_name":"MedSIR","has_results":false},{"nct_id":"NCT05640778","title":"Neoadjuvant Dalpiciclib Plus Aromatase Inhibitors in Luminal B/HER2-negative Breast Cancer (DANCER)","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}